Neurogenesis Inc
Neurogenesis, Inc. manufactures and sells nutritional supplements primarily in the United States. The company offers NeuBecalm'd, a nutritional supplement to reduce the effects of acute and chronic stress factors; NeuBecalm'd Chewables that reduces the effects of stress and enhance focus; and NeuRecover, a nutritional support for the natural replenishment of neurotransmitters depleted by the long… Read more
Neurogenesis Inc (NEUN) - Net Assets
Latest net assets as of September 2011: $-79.19K USD
Based on the latest financial reports, Neurogenesis Inc (NEUN) has net assets worth $-79.19K USD as of September 2011.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($60.51K) and total liabilities ($139.71K). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-79.19K |
| % of Total Assets | -130.88% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
Neurogenesis Inc - Net Assets Trend (2002–2013)
This chart illustrates how Neurogenesis Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Neurogenesis Inc (2002–2013)
The table below shows the annual net assets of Neurogenesis Inc from 2002 to 2013.
| Year | Net Assets | Change |
|---|---|---|
| 2013-12-31 | $-105.70K | +31.38% |
| 2012-12-31 | $-154.03K | -26.87% |
| 2011-12-31 | $-121.41K | -14888.64% |
| 2006-12-31 | $-810.00 | +92.12% |
| 2004-12-31 | $-10.28K | +86.61% |
| 2003-12-31 | $-76.74K | +54.77% |
| 2002-12-31 | $-169.67K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Neurogenesis Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 989500.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2013)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $708.92 | % |
| Other Comprehensive Income | $10.13K | % |
| Other Components | $2.29 Million | % |
| Total Equity | $-105.70K | 100.00% |
Neurogenesis Inc Competitors by Market Cap
The table below lists competitors of Neurogenesis Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Dominion Resources Black Warrior Trust
PINK:DOMR
|
$0.93 |
|
Gritstone bio, Inc.
NASDAQ:GRTSQ
|
$0.93 |
|
Greenbelt Resources Corp
PINK:GRCO
|
$0.93 |
|
Triumph Apparel Corporation
PINK:TRUA
|
$0.93 |
|
Sfsb Inc
PINK:SFBI
|
$0.93 |
|
APT Moto Vox Group Inc
PINK:MTVX
|
$0.93 |
|
China BCT Pharmacy Group Inc
PINK:CNBI
|
$0.93 |
|
Kenergy Scientific Inc
PINK:MSGP
|
$0.93 |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Neurogenesis Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2012 to 2013, total equity changed from -154,032 to -105,699, a change of 48,333.
- Net income of 15,611 contributed positively to equity growth.
- Other comprehensive income increased equity by 10,131.
- Other factors increased equity by 22,591.
Equity Change Factors (2012 to 2013)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $15.61K | +14.77% |
| Other Comprehensive Income | $10.13K | +9.58% |
| Other Changes | $22.59K | +21.37% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Neurogenesis Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2002-12-31 | $0.00 | $0.00 | x |
| 2003-12-31 | $0.00 | $0.00 | x |
| 2004-12-31 | $0.00 | $0.00 | x |
| 2006-12-31 | $0.00 | $0.00 | x |
| 2011-12-31 | $0.00 | $0.00 | x |
| 2012-12-31 | $0.00 | $0.00 | x |
| 2013-12-31 | $0.00 | $0.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Neurogenesis Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 3.91%
- • Asset Turnover: 4.55x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is below the historical average (0.00%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2002 | 0.00% | 1.96% | 6.22x | 0.00x | $42.85K |
| 2003 | 0.00% | 4.46% | 6.64x | 0.00x | $107.82K |
| 2004 | 0.00% | 0.66% | 6.65x | 0.00x | $17.46K |
| 2006 | 0.00% | 0.67% | 6.60x | 0.00x | $8.58K |
| 2011 | 0.00% | -10.16% | 8.58x | 0.00x | $-45.08K |
| 2012 | 0.00% | -6.93% | 16.41x | 0.00x | $-17.24K |
| 2013 | 0.00% | 3.91% | 4.55x | 0.00x | $26.18K |
Industry Comparison
This section compares Neurogenesis Inc's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $580,491,146
- Average return on equity (ROE) among peers: -45.37%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Neurogenesis Inc (NEUN) | $-79.19K | 0.00% | N/A | $0.93 |
| Ascend Wellness Holdings Inc (AAWH) | $142.87 Million | -33.75% | 5.44x | $48.90 Million |
| AB Science S.A (ABSCF) | $14.78 Million | -64.19% | 0.99x | $39.89 Million |
| Alterola Biotech Inc (ABTI) | $-241.47K | 0.00% | 0.00x | $603.58K |
| Aurora Cannabis Inc (ACB) | $521.74 Million | -329.21% | 0.78x | $194.64 Million |
| Acreage Holdings Inc (ACRDF) | $494.79 Million | -30.37% | 0.40x | $13.48K |
| Acura Pharmaceuticals Inc (ACUR) | $37.06 Million | 39.05% | 0.16x | $13.20K |
| Agra Ventures Ltd. (AGFAF) | $1.51 Million | -44.22% | 0.06x | $298.23K |
| Allergy Therapeutics plc (AGYTF) | $32.70 Million | -18.88% | 0.16x | $25.30 Million |
| Aida Pharmaceuticals Inc (AIDA) | $21.19 Million | 12.93% | 1.96x | $1.84 |
| Adcock Ingram Holdings Limited (AIHLF) | $4.54 Billion | 14.90% | 0.58x | $85.61 Million |